Context Therapeutics Inc.

NasdaqCM:CNTX Stock Report

Market Cap: US$22.1m

Context Therapeutics Management

Management criteria checks 3/4

Context Therapeutics' CEO is Martin Lehr, appointed in Jan 2015, has a tenure of 9.17 years. total yearly compensation is $1.06M, comprised of 45.1% salary and 54.9% bonuses, including company stock and options. directly owns 6.14% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 2.6 years and 3 years respectively.

Key information

Martin Lehr

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage45.1%
CEO tenure9.2yrs
CEO ownership6.1%
Management average tenure2.6yrs
Board average tenure3yrs

Recent management updates

Recent updates

We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Mar 27
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Sep 28
Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Jun 05
Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24

Sep 27

We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Sep 15
We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Context Therapeutics GAAP EPS of -$0.25 in-line

Aug 11

Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Aug 02

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

May 28
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

Nov 02

CEO Compensation Analysis

How has Martin Lehr's remuneration changed compared to Context Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$24m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$477k

-US$15m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$2mUS$291k

-US$10m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$648k

Dec 31 2020US$250kUS$250k

US$1m

Dec 31 2019US$250kUS$250k

-US$6m

Compensation vs Market: Martin's total compensation ($USD1.06M) is above average for companies of similar size in the US market ($USD662.11K).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.


CEO

Martin Lehr (39 yo)

9.2yrs

Tenure

US$1,057,653

Compensation

Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. He was a...


Leadership Team

NamePositionTenureCompensationOwnership
Martin Lehr
Co-Founder9.2yrsUS$1.06m6.14%
$ 1.4m
Jennifer Minai-Azary
CFO & Treasurer2.3yrsUS$680.67k0.25%
$ 55.3k
Alex Levit
Chief Legal Officer & Corporate Secretary2.9yrsUS$653.10k0.39%
$ 85.7k
Christopher Beck
Senior Vice President of Operations2.2yrsno datano data

2.6yrs

Average Tenure

44yo

Average Age

Experienced Management: CNTX's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martin Lehr
Co-Founder9.2yrsUS$1.06m6.14%
$ 1.4m
Richard Jay Berman
Independent Chairman of the Board3yrsUS$149.20k0%
$ 0
Jennifer Stacey
Independent Director3yrsUS$97.31k0%
$ 0
Linda West
Independent Director3yrsUS$100.81k0%
$ 0
Philip Kantoff
Independent Director5.3yrsUS$80.81k0.022%
$ 4.9k

3.0yrs

Average Tenure

64yo

Average Age

Experienced Board: CNTX's board of directors are considered experienced (3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.